Triumvira Immunologics to Showcase Clinical Findings from TACTIC-2 Clinical Trial Assessing TAC01-HER2 at 2023 ESMO World Congress on Gastrointestinal Cancer

AUSTIN, Texas, HAMILTON, ON, and SOUTH SAN FRANCISCO, Calif., June 28, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid…

Click here to view original post